The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study

Sebastiano Emanuele Torrisi, Brett Ley, Michael Kreuter, Marlies Wijsenbeek, Eric Vittinghoff, Harold R. Collard, Carlo Vancheri

Source: Eur Respir J, 53 (3) 1801587; 10.1183/13993003.01587-2018
Journal Issue: March
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Sebastiano Emanuele Torrisi, Brett Ley, Michael Kreuter, Marlies Wijsenbeek, Eric Vittinghoff, Harold R. Collard, Carlo Vancheri. The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. Eur Respir J, 53 (3) 1801587; 10.1183/13993003.01587-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis
Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis
Year: 2019



Multi-institutional prospective cohort study of prognostic factors in patients with idiopathic pulmonary fibrosis receiving long-term oxygen therapy.
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019


Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study
Source: ERJ Open Res, 8 (1) 00443-2021; 10.1183/23120541.00443-2021
Year: 2022



Aspergillus pulmonary disease in cystic fibrosis (CF) patients: multicentre perspective observational study based on new diagnostic tests to evaluate the prognostic value on the CF disease
Source: Virtual Congress 2021 – Adult cystic fibrosis
Year: 2021



Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study
Source: Eur Respir J, 53 (2) 1801186; 10.1183/13993003.01186-2018
Year: 2019



D-dimer as a predictor of persistent pulmonary function impairment after COVID-19 pneumonia: a prospective observational study
Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases
Year: 2021


PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients
Source: International Congress 2016 – IPF clinical
Year: 2016

STARMAP: an observational study to assess disease-relevant outcomes using home-monitoring devices in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019


Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study
Source: ERJ Open Res, 6 (1) 00172-2019; 10.1183/23120541.00172-2019
Year: 2020



The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies
Source: Eur Respir J, 51 (6) 1800376; 10.1183/13993003.00376-2018
Year: 2018



Persistent lung abnormalities versus established fibrosis: a prospective study of COVID-19 follow-up
Source: Virtual Congress 2021 – Long COVID - 19
Year: 2021


PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015


Body composition and mortality in idiopathic pulmonary fibrosis (IPF): a prospective cohort study.
Source: International Congress 2018 – Let’s interact and discuss the hot topics in pulmonary rehabilitation
Year: 2018



1-year prospective study in severe COPD patients: marker of inflammation, lung function and radiologic evaluation
Source: Annual Congress 2007 - Pathophysiology and assessment of COPD
Year: 2007


Late Breaking Abstract - A composite serum biomarker index for the diagnosis of systemic sclerosis associated interstitial lung disease: a multicentre, observational, cohort study
Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Year: 2021



Edu-Care®, a randomised, multicentre study on education and quality of life in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 211s
Year: 2002

Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2003 - Interstitial lung diseases
Year: 2003


Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


Home oxygen saturation monitoring and quality of life in patients with idiopathic pulmonary fibrosis: A prospective multicenter trial
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013

Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Source: Eur Respir J 2012; 40: 101-109
Year: 2012